Stockholm 3 - An advanced PSA test
Stockholm3 is a combination of several different biomarkers (total PSA, free PSA, hK2, MSMB, MIC1 and 101 genetic markers) in combination with your age, previous prostate biopsy and heredity for prostate cancer.
The result is a Risk Score that indicates the risk of prostate cancer requiring treatment and provides recommendations for further measures.
Why choose Stockholm3 over a regular PSA test?
Early and accurate detection of treatment-requiring prostate cancer is crucial, especially in the case of suspicion in combination with occurrence within the family. Stockholm3 is a ground-breaking PSA test that offers just this, by combining advanced technology and analysis method.
A more accurate PSA test
Stockholm3, detects 100 percent more cancer cases requiring treatment compared to the traditional PSA test. This provides the conditions for early detection and effective treatment of prostate cancer. In addition, Stockholm3 reduces the number of unnecessary biopsies, saving you from potential complications and discomfort.
Recommendations based on risk level
A regular PSA test can be difficult to interpret and often does not provide sufficient guidance for next steps. Stockholm3 not only provides a Risk Score but also clear recommendations based on your specific risk level. Almost 50 percent of the men who undergo the Stockholm3 test turn out to have such a low risk that they do not need a new test until six years from now. This saves time, money and worry for many.
The difference between Stockholm3 and a traditional PSA test
Stockholm3 identifies almost all cases of prostate cancer requiring treatment, while a regular PSA test may miss some of these cases. A PSA test cannot distinguish between dangerous and harmless cancer, which often leads to unnecessary biopsies of the prostate. Biopsies can cause side effects. The Stockholm3 test reduces the number of unnecessary biopsies by half. The results from a PSA test can be difficult to interpret, while Stockholm3 gives clear recommendations based on risk level. Almost 50% of the men who have taken the Stockholm3 test have had such a low risk that they do not need to take another test until six years from now.
Interpretation of your test answers
The result from the Stockholm3 test consists of two different parts:
- Stockholm3 Risk Score: A risk assessment that indicates the probability that the patient has prostate cancer requiring treatment (ISUP ≥ 2) at biopsy.
- Stockholm3 Recommendation: A recommendation for further care based on the risk assessment.
Response categories for Stockholm3 Recommendation
- Low risk: Stockholm3 Risk Score 0-3%
- Normal risk: Stockholm3 Risk Score 4-10%
- Increased risk with volume cut-off: Stockholm3 Risk Score 11-29%
- Increased risk without volume cut-off: Stockholm3 Risk Score ≥ 30%
- Increased risk without volume cut-off: Stockholm3 Risk Score 11-29%
Delivered results based on risk level
- Increased risk (Stockholm3 Risk Score ≥ 11):
- Stockholm3 Risk Score
- Total PSA
- Stockholm3 Prostate Volume Cut-Off (if applicable)
- Normal risk (Stockholm3 Risk Score 4-10):
- Stockholm3 Risk Score
- Total PSA
- Low risk (Stockholm3 Risk Score
- Stockholm3 Risk Score
- Total PSA with response ≤ 1.5 ng/ml